Zevra Therapeutics (NASDAQ:ZVRA) PT Lowered to $22.00 at Canaccord Genuity Group
Zevra Therapeutics (NASDAQ:ZVRA – Free Report) had its price objective decreased by Canaccord Genuity Group from $24.00 to $22.00 in a report issued on Wednesday morning, Benzinga reports. Canaccord Genuity Group currently has a buy rating on the stock. Several other research firms also recently commented on ZVRA. William Blair upgraded shares of Zevra Therapeutics […]
More Stories
NexPoint Real Estate Finance (NYSE:NREF) Downgraded by Raymond James
Raymond James cut shares of NexPoint Real Estate Finance (NYSE:NREF – Free Report) from a strong-buy rating to a market...
ICON Public (NASDAQ:ICLR) Downgraded by StockNews.com
StockNews.com lowered shares of ICON Public (NASDAQ:ICLR – Free Report) from a buy rating to a hold rating in a...
StockNews.com Lowers Delcath Systems (NASDAQ:DCTH) to Sell
StockNews.com downgraded shares of Delcath Systems (NASDAQ:DCTH – Free Report) from a hold rating to a sell rating in a...
Dynagas LNG Partners (NYSE:DLNG) Upgraded at StockNews.com
StockNews.com upgraded shares of Dynagas LNG Partners (NYSE:DLNG – Free Report) from a buy rating to a strong-buy rating in...
Smith Douglas Homes (NYSE:SDHC) PT Raised to $40.00
Smith Douglas Homes (NYSE:SDHC – Free Report) had its price target lifted by Bank of America from $36.00 to $40.00...
BeiGene (NASDAQ:BGNE) Now Covered by Analysts at JMP Securities
JMP Securities began coverage on shares of BeiGene (NASDAQ:BGNE – Free Report) in a research note released on Wednesday, Marketbeat...